|
Post by sportsrancho on Oct 26, 2018 14:57:48 GMT -5
So..I couldn’t wait to read the next chapter and find out exactly what this person meant by the Calvary is coming. It was over whelming evidence on the defendant side that made minced meat out of the prosecutor’s case. A first win for the new attorney.
|
|
|
Post by sportsrancho on Oct 26, 2018 14:59:04 GMT -5
Wish I was you:-) you’re loaded, set for whatever comes and can wait it out. I’m hoping we get a little bump next week so I can roll calls and re-load for 2021. Safe haven in this market! Last night I was reading my book by James Patterson, The Third juror...there was a man accused of a horrific murder,he did not commit. His women attorney was very wet behind the ears. And old associate came to her with some very important evidence, they made arrangements to meet later in the day. The attorney looked worried, and said, can’t you tell me anything now? and her friend said, not to worry the “Calvary is coming!” I just had to put my book down and laugh! What are the odds... Why not buy the shares themselves? At the current price, the shares are a bargain to me in comparison to the 2021 calls. You will have peace of mind as well holding the shares rather than the calls. I am completely tapped out. No dry powder.
|
|
|
Post by pat on Oct 26, 2018 15:08:33 GMT -5
Leverage. (Roughly) twice the bang for the buck.
Now just need the Big Bang.
|
|
|
Post by mnholdem on Oct 27, 2018 6:13:58 GMT -5
CEO Castagna: Please update shareholders on why there’s been virtually no Medicare coverage for Afrezza and whether it has been approved for 2019. Thank you!
|
|
|
Post by sportsrancho on Oct 27, 2018 7:35:06 GMT -5
|
|
|
Post by hellodolly on Oct 27, 2018 7:52:34 GMT -5
I think the timing is bullish. Just dug up an old paper: Timing of earnings release. Releasing good news during (or before) trading and bad news after hours has been common for years. See also Investopedia. Good things ahead!
All of those late earnings releases for apple and netflix have been poor. One offs this Q. Regardless, performance drives SP for top and bottom line expectations on both of those examples. We're still counting scripts weekly, lol.
|
|
|
Post by mannmade on Oct 27, 2018 10:21:33 GMT -5
I believe Garrett Ingram is Chief Marketing Officer. Mike was Chief Commercial Officer as I recall. 😊
|
|
|
Post by mango on Oct 27, 2018 10:36:45 GMT -5
I loaded up on more 2021 $4 call options today. I am so, so long. While I hope Mike announces world peace on Thursday I am resigning myself to another 6 months of drudgery. Wish I was you:-) you’re loaded, set for whatever comes and can wait it out. I’m hoping we get a little bump next week so I can roll calls and re-load for 2021. Safe haven in this market! Last night I was reading my book by James Patterson, The Third juror...there was a man accused of a horrific murder,he did not commit. His women attorney was very wet behind the ears. An old associate came to her with some very important evidence, they made arrangements to meet later in the day. The attorney looked worried, and said, can’t you tell me anything now? and her friend said, not to worry the “Calvary is coming!” I just had to put my book down and laugh! What are the odds... The odds are about like that of Ruby Bozarth moving to Mississippi where I live to practice law, and me just last month receiving a jury duty notice.
|
|
|
Post by figglebird on Oct 27, 2018 11:34:07 GMT -5
allot to talk aboit and consider - much has transpired in 3 months.
to start, should recall last quarters conference call which to me was the first and possibly most meaningful window into new Management's ability to essentially Channel Al Mann and for the first time seize the narrative particularly with respect to how to think about a frezza as a novel game-changing insulin - and with that brings new metrics exclusive to ts to measure a new and Progressive effort -instead of old metrics that otherwise represent a failing effort against diabetes and a profitable one at that - it has been those old metrics that have made it so transparent yet easy for anyone barish on this brand of dpi insulin to be non-inferior old testing simply does not fit and one patient at a time spoke to Mike's steady approach that perfectly shadowed what was to come.
Upcoming November 1st the two most important issues as I see it would be the internal progress of Management's ability to control the company DEER FIELD - have there been as stated changes to the facility agreement are we closed this is crucial and of course more disclosure into United therapeutic deals FDA approval expectations and schedule and additional any additional Partners.
Best case scenario if things are as expected to be on the up-and-up I would like management to address broader risks more succinctly of being an independent dry powder inhaler company one of the only to have an FDA approved API and another on the way
|
|
|
Post by alethea on Oct 29, 2018 12:54:43 GMT -5
CEO Castagna: Please update shareholders on why there’s been virtually no Medicare coverage for Afrezza and whether it has been approved for 2019. Thank you! Not for me it hasn't. Hasn't been approved that is. I met with my Medicare plans sales rep. Absolutely NO plans with any coverage whatsoever for Afrezza here in my part of Iowa for Medicare participants. I confirmed this with my own internet searches. It would/will cost me about $1,000 per month out of pocket. I can't afford that. Thanks Castagna for leaving me and millions of other Medicare insureds to die as far as you are concerned. So much for Al Mann's plans to help the tens of millions afflicted with diabetes. So much for Al's plan to help Mankind. And you're too stupid to see that a major price reduction would vastly improve sales for millions of Medicare customers. And ironically make you a vastly more wealthy man.
|
|
|
Post by uvula on Oct 29, 2018 13:13:36 GMT -5
Alethea:
Wow. I can understand your frustration but your post is way over the top. And a major price reduction would probably destroy the company. Things are looking up. Hang in there.
|
|
|
Post by peppy on Oct 29, 2018 13:24:14 GMT -5
CEO Castagna: Please update shareholders on why there’s been virtually no Medicare coverage for Afrezza and whether it has been approved for 2019. Thank you! Not for me it hasn't. Hasn't been approved that is. I met with my Medicare plans sales rep. Absolutely NO plans with any coverage whatsoever for Afrezza here in my part of Iowa for Medicare participants. I confirmed this with my own internet searches. It would/will cost me about $1,000 per month out of pocket. I can't afford that. Thanks Castagna for leaving me and millions of other Medicare insureds to die as far as you are concerned. So much for Al Mann's plans to help the tens of millions afflicted with diabetes. So much for Al's plan to help Mankind. And you're too stupid to see that a major price reduction would vastly improve sales for millions of Medicare customers. And ironically make you a vastly more wealthy man. Alethea, Grassley. #%$^@*
|
|
|
Post by alethea on Oct 29, 2018 14:04:18 GMT -5
Alethea: Wow. I can understand your frustration but your post is way over the top. And a major price reduction would probably destroy the company. Things are looking up. Hang in there. Over the top? I hardly think so. Afrezza is priced like a Ferrari or Bentley.... when it needs to be priced liked a Toyota Corolla... thereby increasing script sales by 5 or 10 times. And the point is cutting the price in half might triple or quadruple the sales. What good is a miracle drug if less than a small fraction of 1% of the people who need it can ever get it. Al said he wanted to help diabetics and the simple reality is that very, VERY FEW are being helped at this ridiculously exorbitant price.
|
|
|
Post by uvula on Oct 29, 2018 14:15:10 GMT -5
Mnkd could just give it away for free. Which would be great for you until the company goes bankrupt. And then no one will benefit.
I am sure that if there was an obvious simple solution like lowering the price Mike would be aware of it.
|
|
|
Post by peppy on Oct 29, 2018 14:28:52 GMT -5
Alethea: Wow. I can understand your frustration but your post is way over the top. And a major price reduction would probably destroy the company. Things are looking up. Hang in there. Over the top? I hardly think so. Afrezza is priced like a Ferrari or Bentley.... when it needs to be priced liked a Toyota Corolla... thereby increasing script sales by 5 or 10 times. And the point is cutting the price in half might triple or quadruple the sales. What good is a miracle drug if less than a small fraction of 1% of the people who need it can ever get it. Al said he wanted to help diabetics and the simple reality is that very, VERY FEW are being helped at this ridiculously exorbitant price. quote: What good is a miracle drug if less than a small fraction of 1% of the people who need it can ever get it. reply: owning MNKD has been a wake up call. One of the wake ups I have had is this is the way OUR system works. We only realize it now, because it affects us. So let's get real. here in the USA our motto seems to be, how does this affect me? case in point: Chromium-6 in Tap Water: Why the 'Erin Brockovich' Chemical Is Dangerous. Did you care the people got sick and died? Was it PG&E? www.livescience.com/56210-what-is-chromium-6-in-tap-water.htmlHow about that lead in the water in Michigan? Upsetting? #take back our power?
|
|